Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabaletta in OPMD (HOPEMD)
NCT02328482Phase 3Completed
- Sponsor
- Bioblast Pharma Ltd.
- Start
- Jan 2015
- Primary completion
- Oct 2017
- Modality
- Drug Delivery Systems, DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of trehalose in oculopharyngeal muscular dystrophy (OPMD), sponsored by Bioblast Pharma Ltd.. Started Jan 2015; status: completed.
02
Drugs
trehalose
03
Conditions
oculopharyngeal muscular dystrophy (OPMD)
Beyond the preview
Go deeper on NCT02328482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328482.